LENZ - LENZ Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.00
DETAILS
HIGH:
$12.00
LOW:
$12.00
MEDIAN:
$12.00
CONSENSUS:
$12.00
UPSIDE:
145.90%
About LENZ Therapeutics, Inc. (https://www.lenz-tx.com)
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Evert Schimmelpennink | President, Chief Executive Officer, Secretary & Director | 1972 | $1,242,200 USD |
| Marc G. Odrich | Chief Medical Officer | 1959 | $774,000 USD |
| Shawn Olsson | Chief Commercial Officer | 1983 | $724,600 USD |
| Daniel R. Chevallard | Chief Financial Officer | 1980 | $680,368 USD |
| James W. McCollum | Co-Founder & Director | 1955 | $40,000 USD |
| David Choromanski | Vice President of Marketing | – | – |
| Domenick Porfidia | Vice President of Sales | – | – |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | – | – |
| Melissa Rosness | Senior Vice President of Manufacturing Operations | – | – |